Morria Biopharmaceuticals Plc to Present at the Rodman & Renshaw 10th Annual Healthcare ... ( LONDON and NEW YORK Oct. 30 /- Mo...)

Morria Biopharmaceuticals Plc to Present at the Rodman & Renshaw 10th Annual Healthcare Conference

Date:10/30/2008

LONDON and NEW YORK, Oct. 30 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focusing on first-in-class novel, non-steroidal anti-inflammatory drugs, announced today that Dr. Yuval Cohen, President of Morria, will deliver a presentation at the Rodman & Renshaw 10th Annual Healthcare Conference on Monday, Nov. 10 from 10:45 to 11:10 a.m. in the Louis room (4th Floor) at The New York Palace Hotel.

Dr. Cohen's presentation will provide an overview of Morria's development of its leading clinical programs in allergic rhinitis (hay fever) and skin inflammation (contact dermatitis), as well as its pre-clinical progress in asthma, inflammatory bowel disease, ophthalmology and cystic fibrosis. The presentation will include a review of the clinical results reported from Morria's recently completed Phase II double blind placebo controlled study in 105 patients suffering from allergic rhinitis, a study that also included a steroid comparator.

ABOUT MORRIA BIOPHARMACEUTICALS Plc

Morria Biopharmaceuticals Plc is a biopharmaceutical company focusing on the development of novel, anti-inflammatory pharmaceuticals termed Multi-Functional Anti-Inflammatory Drugs (MFAID). Morria is determined to become a pivotal player in the anti-inflammatory drug market through the introduction of novel drugs for the treatment of a variety of acute and chronic inflammatory conditions including respiratory, skin, airway and gastro-intestinal inflammatory diseases. For more information please visit http://www.morria.com.

This is not an invitation nor is it an offer to purchase or subscribe for shares. This release is only intended for persons falling within the exception set out in regulation 47 of the Financial Promotion order - Persons in the business of disseminating information.

Richard Lewis Communications, Inc.

212-827-0020

Cecelia Heer - Investors

'/>"/>

SOURCE Morria Biopharmaceuticals Plc
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related biology technology :

1. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
2. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
3. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
4. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
5. Nomad Bioscience: New Plant Biotechnology Company Founded to Focus on Biomaterials and Biopharmaceuticals
6. Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants
7. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
9. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
10. XTL Biopharmaceuticals Announces Appointment of Laurence N. Charney to Board of Directors
11. XTL Biopharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference

Post Your Comments:

(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Drug Discovery Technologies - A Global Update of Market Trends & Opportunities ,,

(Date:12/2/2009)CALGARY, Dec. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ: ONCY ) announced today that in connection with its previously announced unit offering

(Date:12/2/2009)JERUSALEM, Israel, December 2 Gamida Cell announced today,a feasibility study evaluating the preclinical (animal study) safety and,efficacy of a gene therapy product which combines technology from We

(Date:12/2/2009)QUEBEC CITY, Dec. 2 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today annou

[0] Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities [0] Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option [0] Gamida Cell Announces Feasibility Study With Weill Cornell Medical College [0] AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma

...ons is pleased to welcome Richard Duffey, M.D., to...in Mobile, Alabama and also serves patients from P...and Pascagoula communities in Mississippi.,Trusted... LASIK Eye Surgeons directory service and informat...geons.com . What sets the Trusted LASIK Surgeons d...

...tion (OTC: MYMX), will be holding an important con... New York Time to update all shareholders,on the r...Form 10-Q and to,address recent press articles., ...866-591-4361 PIN 815,726 and from Europe at +41-80...Mymetics, primary objective is to develop vaccines...

...aqGS: VARI) introduced its new dual wavelength X-r...les and proteins. The SuperNova(TM) is the,first d...high intensity,micro-source X-ray technology. It i...ata analysis, enabling faster results even for the... diffraction is used to determine the structure of...

Other Biology Technology:Trusted LASIK Surgeons Welcomes Mobile Alabama Expert Refractive Eye Surgeon Richard Duffey, M.D. to Its LASIK Directory For Consumers 2 Trusted LASIK Surgeons Welcomes Mobile Alabama Expert Refractive Eye Surgeon Richard Duffey, M.D. to Its LASIK Directory For Consumers 3 Trusted LASIK Surgeons Welcomes Mobile Alabama Expert Refractive Eye Surgeon Richard Duffey, M.D. to Its LASIK Directory For Consumers 4 Trusted LASIK Surgeons Welcomes Mobile Alabama Expert Refractive Eye Surgeon Richard Duffey, M.D. to Its LASIK Directory For Consumers 5 Trusted LASIK Surgeons Welcomes Mobile Alabama Expert Refractive Eye Surgeon Richard Duffey, M.D. to Its LASIK Directory For Consumers 6 New Dual Wavelength X-ray Diffractometer From Oxford Diffraction, Now a Part of Varian, Inc., Allows Increased Throughput for Challenging Single Crystal Analyses 2

Trusted LASIK Surgeons Welcomes Mobile Alabama Expert Refractive Eye Surgeon Richard Duffey, M.D. to Its LASIK Directory For Consumers Mymetics Corporation Important Shareholders Information Conference Call New Dual Wavelength X-ray Diffractometer From Oxford Diffraction, Now a Part of Varian, Inc., Allows Increased Throughput for Challenging Single Crystal Analyses

(Date:12/3/2009)UPTON, NY A team of scientists from the U.S. Department of Energy,s (DOE) Brookhaven National Laboratory, Harvard University, and the Indian Institute of Science has made a major step in understandin

(Date:12/2/2009)PHILADELPHIA New study results strengthen the evidence that people who smoke cigarettes over a long period of time have an increased risk for developing colorectal cancer, even after adjusting for ot

(Date:12/2/2009)PHILADELPHIA Exposure to secondhand smoke for a prolonged period of time and in high quantity may increase the risk of breast cancer, even in women who never smoked cigarettes themselves. , "The qu

Breaking Biology News(10 mins):Grooving down the helix 2 Grooving down the helix 3 Cigarette smoking increases colorectal cancer risk 2 Exposure to secondhand cigarette smoke over a lifetime increased breast cancer risk later in life 2 Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 1 Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 2 Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 3 Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 4 Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 5 Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 6 Shire Reports Tolerability and Clinical Effects Results of Daytrana 28R 29 28methylphenidate transdermal system 29 from Study in Adolescents with ADH 5890 7 Gen Probe to Webcast Two Upcoming Investor Presentations 5888 1 Gen Probe to Webcast Two Upcoming Investor Presentations 5888 2 Patients More Likely to Die While in ICU in U S Than in England 60428 1 Patients More Likely to Die While in ICU in U S Than in England 60428 2

[0] Grooving down the helix [0] Cigarette smoking increases colorectal cancer risk [0] Exposure to secondhand cigarette smoke over a lifetime increased breast cancer risk later in life

...ommonwealth University Massey Cancer Center have f...ement of human breast cancer cells toward epiderma...nal of Biological Chemistry, researchers showed th... role in breast cancer progression, stimulates sph...nzymes that forms the potent lipid mediator, sphin...

...ar subtleties of a strain of mice engineered to ag...ion of genetic mutations prompts a cascade of prog... process. , Writing today (July 15, 2005) in the j...sity of Wisconsin-Madison geneticist Tomas A. Prol... normal mice that peel away some of the root secre...

...global health threat. Although more than 3 billion...o fight tuberculosis, the ability of the BCG vacci...ficacy against newly emerging isolates. , In a stu...nt publication of the September 1 issue of the Jou...d colleagues from the Max Planck Institute devise ...

Other Biology News:Elderly mice yield clues to the process of growing old 2 Elderly mice yield clues to the process of growing old 3

VCU Massey Cancer Center study shows enzyme linked to spread of breast cancer cells Elderly mice yield clues to the process of growing old Agilent Technologies Introduces First Commercial Mouse Microarray for Comparative Genomic Hybridization Research

T7 RNA Polymerase from Invitrogen

T7 RNA polymerase from Chimerx

Hexokinase/ Glucose-6-Phosphate Dehydrogenase from Roche Applied Science

RNase H from Roche Applied Science

Biology Products:

T7 RNA Polymerase from Invitrogen T7 RNA polymerase from Chimerx Hexokinase/ Glucose-6-Phosphate Dehydrogenase from Roche Applied Science RNase H from Roche Applied Science

Morria Biopharmaceuticals Plc to Present at the Rodman & Renshaw 10th Annual Healthcare ...( LONDON and NEW YORK Oct. 30 /- Mo...)